Cargando…

Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.

Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated with conventional therapies. Significant efforts have been made in recent years to bring a broad spectrum of novel targeted therapies, the most notewo...

Descripción completa

Detalles Bibliográficos
Autores principales: Paillassa, Jérôme, Safa, Firas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728095/
https://www.ncbi.nlm.nih.gov/pubmed/35024331
http://dx.doi.org/10.1016/j.lrr.2021.100282
_version_ 1784626658803712000
author Paillassa, Jérôme
Safa, Firas
author_facet Paillassa, Jérôme
Safa, Firas
author_sort Paillassa, Jérôme
collection PubMed
description Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated with conventional therapies. Significant efforts have been made in recent years to bring a broad spectrum of novel targeted therapies, the most noteworthy of which is chimeric antigen receptor T-cell therapy (CAR-T). Not all patients are eligible for CAR-T given the relatively high risk of complications and limited availability. Here we discuss promising novel biologic therapies that have been introduced in the last few years and go over ongoing clinical trials in the field.
format Online
Article
Text
id pubmed-8728095
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87280952022-01-11 Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer. Paillassa, Jérôme Safa, Firas Leuk Res Rep Article Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated with conventional therapies. Significant efforts have been made in recent years to bring a broad spectrum of novel targeted therapies, the most noteworthy of which is chimeric antigen receptor T-cell therapy (CAR-T). Not all patients are eligible for CAR-T given the relatively high risk of complications and limited availability. Here we discuss promising novel biologic therapies that have been introduced in the last few years and go over ongoing clinical trials in the field. Elsevier 2021-12-10 /pmc/articles/PMC8728095/ /pubmed/35024331 http://dx.doi.org/10.1016/j.lrr.2021.100282 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Paillassa, Jérôme
Safa, Firas
Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
title Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
title_full Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
title_fullStr Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
title_full_unstemmed Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
title_short Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
title_sort novel biologic therapies in relapsed or refractory diffuse large b cell lymphoma: car-t is not the only answer.
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728095/
https://www.ncbi.nlm.nih.gov/pubmed/35024331
http://dx.doi.org/10.1016/j.lrr.2021.100282
work_keys_str_mv AT paillassajerome novelbiologictherapiesinrelapsedorrefractorydiffuselargebcelllymphomacartisnottheonlyanswer
AT safafiras novelbiologictherapiesinrelapsedorrefractorydiffuselargebcelllymphomacartisnottheonlyanswer